+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Rivastigmine"

Alzheimer's Drugs Global Market Report 2024 - Product Thumbnail Image

Alzheimer's Drugs Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Transdermal CNS Therapeutics to 2028 - Product Thumbnail Image

Transdermal CNS Therapeutics to 2028

  • Report
  • July 2023
  • 115 Pages
  • Global
From
Alzheimer's Disease Drugs - Global Strategic Business Report - Product Thumbnail Image

Alzheimer's Disease Drugs - Global Strategic Business Report

  • Report
  • April 2024
  • 93 Pages
  • Global
From
From
From
Alzheimer's Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 180 Pages
  • Global
From
From
From
From
From
From
Alzheimer's Therapeutics Market Report 2022-2032 - Product Thumbnail Image

Alzheimer's Therapeutics Market Report 2022-2032

  • Report
  • December 2022
  • 196 Pages
  • Global
From
From
Global Alzheimer's Treatment Market Outlook 2027 - Product Thumbnail Image

Global Alzheimer's Treatment Market Outlook 2027

  • Report
  • June 2020
  • 163 Pages
  • Global
From
Loading Indicator

Rivastigmine is a drug used to treat symptoms of Alzheimer's disease and other forms of dementia. It is a cholinesterase inhibitor, meaning it works by increasing the amount of a chemical messenger in the brain that helps nerve cells communicate with each other. It is used to treat mild to moderate dementia caused by Alzheimer's disease or Parkinson's disease. It is also used to treat mild to moderate dementia caused by Lewy body dementia. Rivastigmine is available in both capsule and patch form. Rivastigmine is part of the Central Nervous System (CNS) drugs market, which includes drugs used to treat neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. CNS drugs are used to treat a wide range of conditions, from mild to severe. The CNS drugs market is highly competitive, with many companies offering similar products. Some companies in the Rivastigmine market include Novartis, Pfizer, Mylan, and Teva Pharmaceuticals. Show Less Read more